Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy
Recruiting · NCT05584267 · Interventional (participants receive a specific treatment) · Lead sponsor: Hunan Province Tumor Hospital
View the official record on ClinicalTrials.gov →Interventions studied
Chemotherapy + immunotherapyradiotherapy
What this trial is about
This is a prospective multicenter clinical study. This study aims to construct an auxiliary decision-making system for lung cancer immunotherapy combined with radiotherapy by fusing three modes of imagomics, clinicopathological features, and molecular pathological features.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Age ≥ 18 years of age on day of signing informed consent
- Histopathology confirmed non-small cell lung cancer
- Asymptomatic brain metastases
- EGFR/ALK ROS1 driver gene mutation negative
- RECIST 1.1 based available assessment of lesions
- ECOG 0-1
- Brain metastases 1-4
- Single lesion ≤4cm
Exclusion criteria
- Patients with contraindication of chemotherapy Pregnant or breast feeding women
Where it is running
1 location listed.
- Hunan Cancer Hospital - Changsha, Hunan, China